Supernormal Oxygen Delivery for Patients With Severe Burns

Supernormal Oxygen Delivery for Patients With Severe Burns：A Randomized Controlled Trial

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05241912

Enrollment

100

Registered

2022-02-16

Start date

2022-02-28

Completion date

2023-06-01

Last updated

2022-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn Surgery, Dobutamine

Brief summary

This is a randomized double-blinded study to investigate in which the groups are designated as the control group and the goal-directed fluid therapy group to further evaluate significant differences in rate of complications during burn surgery.

Detailed description

This is a randomized double-blinded study to investigate the effect of control group and the goal-directed fluid therapy group on complications during surgery of the burn patients. The groups are designated as the control group and the oal-directed fluid therapy group to further evaluate significant differences in complications during the surgery.

Interventions

DRUGDobutamine

administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Severe burn patients

Exclusion criteria

* Patients or families refuse to sign consent

Design outcomes

Primary

Measure	Time frame	Description
Complication	One week after operation	perioperative complications

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026